title: Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
abstract: OBJECTIVE
  The mechanism responsible for the lipid-lowering effect of dipeptidyl peptidase-4 (DPP-4) inhibitors remains unknown in humans. We evaluated the effect of anagliptin on serum lipid profiles, including cholesterol synthesis and absorption markers, in Japanese patients with type 2 diabetes.
  
  
  METHODS
  Thirty patients with type 2 diabetes (20 - 70 years old, low-density lipoprotein cholesterol (LDL-C) level over 120 mg/dl, and no history of treatment with antidiabetic or antihyperlipidemic drugs) were enrolled. One hundred milligrams of anagliptin were administered twice a day for a month.
  
  
  RESULTS
  After treatment of anagliptin, the LDL-C and total cholesterol (TC) levels did not decrease overall, but the TC level decreased significantly in 28 patients whose HbA1c levels decreased. Lathosterol decreased significantly, whereas no changes in campesterol, sitosterol or cholestanol were observed.
  
  
  CONCLUSIONS
  These results of our study show no significant change in LDL-C, a tendency of decrease in TC and non-high-density lipoprotein cholesterol (non-HDL-C) after treatment of anagliptin for 1 month. Anagliptin therapy decreased the cholesterol synthesis marker lathosterol without changing cholesterol absorption markers.
authors.affiliation: Yokohama City University, Department of Biostatistics , Yokohama , Japan.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Aoki
authors.forename: Takahiro
authors.initials: T
authors.lastname: Ijima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kamiyama
authors.forename: Kazunari
authors.initials: K
authors.lastname: Kamiko
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D004083:Cholestanol / Q000097:blood; D002784:Cholesterol / Q000031:analogs & derivatives / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010840:Phytosterols / Q000097:blood; D010865:Pilot Projects; D011743:Pyrimidines / Q000627:therapeutic use*; D012855:Sitosterols / Q000097:blood; D055815:Young Adult
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D008055:Lipids; D008075:Lipoproteins, HDL; D010840:Phytosterols; D011743:Pyrimidines; D012855:Sitosterols; C021273:campesterol; C025473:gamma-sitosterol; C001521:lathosterol; D004083:Cholestanol; D002784:Cholesterol; C583175:anagliptin
keywords: anagliptin; campesterol; cholestanol; lathosterol; sitosterol; type 2 diabetes